



The Evolving Management of Duchenne Muscular Dystrophy

A PTC-Sponsored Symposium
at the 14th International Congress on Neuromuscular Diseases

12:00 – 13:30 Friday, 8 July 2016
Osgoode Ballroom West
Sheraton Centre Toronto Hotel

Lunch will be served.

To learn more about Duchenne muscular dystrophy or PTC Therapeutics,
please visit our booth #112 at any time during exhibit hours.



Register by scanning this QR code
with your mobile device or by visiting
www.ptcbio.com/ICNMDISS

The Evolving Management of Duchenne Muscular Dystrophy

Programme

12:15–12:25

Welcome and Introduction

Jean K. Mah, MD, MSc, FRCPC (Chair)
*Associate Professor, Departments of Pediatrics and Clinical Neurosciences;
University of Calgary
Director, Pediatric Neuromuscular Program; Alberta Children's Hospital*

12:25–12:45

The Evolving Understanding of Clinical End Points and Meaningfulness

Jean K. Mah, MD, MSc, FRCPC

12:45–13:10

The Future of Duchenne Treatments

Perry Shieh, MD, PhD
*Associate Professor & Director of the Neuromuscular Program, Neurology;
David Geffen School of Medicine at UCLA*

13:10–13:15

Questions and Meeting Close

Jean K. Mah, MD, MSc, FRCPC

Prepared May 2016

This presentation was approved by the Program Committee as an independent activity held in conjunction with the 14th International Congress on Neuromuscular Diseases. This presentation is not sponsored or endorsed by ICNMD 2016.

Organized and funded by PTC Therapeutics, Inc.

www.ptcbio.com